{
    "nct_id": "NCT04147234",
    "official_title": "Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination With Ezabenlimab (BI 754091) in Solid Tumors",
    "inclusion_criteria": "Inclusion criteria\n\n* Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic malignant solid tumor and indication for treatment\n* Patient must have exhausted established treatment options known to prolong survival for the malignant disease, or is not eligible for established treatment options.\n* Medically fit and willing to undergo all mandatory trial procedures.\n* At least one tumor lesion which is suitable for injection (Screening/initial administration), appropriate for the allocated treatment arm, and measurable.\n* At least 1 discrete lesion, in addition to the lesion proposed for injection, which is amenable to biopsy and is not located in the brain, mediastinum or pancreas.\n* Adequate organ function or bone marrow reserve\n* Further inclusion criteria apply\n\nExclusion criteria:\n\n* Any investigational or antitumour treatment (including antibodies targeting Programmed Cell Death-1 (PD1) - or programmed Death-Ligand 1 (PDL1)) within 4 weeks or 5 half-life periods (whichever is shorter) prior to the initial administration of BI 1387446 or BI 754091.\n* Persistent toxicity from previous treatments (including Immune-related Adverse Events (irAEs)) that has not resolved to â‰¤ Grade 1, except for alopecia, xerostomia, and immunotherapy related endocrinopathies which may be included if clinically stable on hormone supplements or antidiabetic drugs as per Investigator judgement\n* History or evidence of active, non-treatment related autoimmune disease, except for endocrinopathies which may be included if clinically stable on hormone supplements or antidiabetic drugs.\n* History or evidence of pneumonitis related to prior immunotherapy\n* Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 2 weeks prior to the first dose of BI 1387446 or BI 754091.\n* The tumor at the projected injection site has a high risk for local complications, e.g. bleeding related to encasement/infiltration of major blood vessels or contact with liver capsule, compression of vital structures in case of swelling of injected lesion, in the opinion of the Investigator.\n* Active infection requiring systemic therapy at the start of treatment in the trial, including active viral hepatitis infection or active tuberculosis infection.\n* Cardiac insufficiency New York Heart Association (NYHA) III or IV\n* Left ventricular ejection fraction < 50% measured by echocardiography or Multigated Acquisition (MUGA) scan\n* Mean resting corrected QT interval (QTc) >470 msec\n* Further exclusion criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}